Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06837987Completed

Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT.

Role: lead

NCT05662956Phase 2Completed

A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Role: lead

NCT06476249Recruiting

Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection

Role: lead

NCT06471478Completed

The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs

Role: lead

NCT06378060Phase 2Recruiting

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

Role: lead

NCT06164821Not ApplicableUnknown

Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Role: lead

NCT05807347Phase 2Unknown

Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Role: lead

All 7 trials loaded